Can You Take Reishi Mushroom With NMN or NR?

What Are NMN and NR, and Why Are Women Taking Them?

NMN and NR are two oral precursors to NAD+ (nicotinamide adenine dinucleotide), a coenzyme your cells use for energy metabolism, DNA repair, and mitochondrial function. NAD+ tissue concentrations decline with age, and that decline appears to track with metabolic and reproductive aging in women specifically.

Women's interest in these supplements has grown sharply over the past five years, largely because of connections researchers are exploring between NAD+ and ovarian aging, perimenopause fatigue, and metabolic shifts around menopause.

How NMN and NR differ

NMN is a larger molecule than NR. In the gut, some NMN is first converted to NR before being absorbed, though a specific intestinal NMN transporter (Slc12a8) allows direct uptake as well, as shown in mouse studies from Washington University. Whether that transporter operates similarly in human women is not yet confirmed. NR enters cells and is phosphorylated to NMN by NRK1, then onward to NAD+. Both routes ultimately raise intracellular NAD+, but their speed and tissue distribution may differ.

Women-specific NAD+ physiology

In reproductive-age women, estrogen signaling interacts with SIRT1, a NAD+-dependent deacetylase involved in ovarian follicle quality. Preclinical data suggest NMN supplementation may support oocyte quality under metabolic stress, though human fertility trial data in women are absent. After menopause, the estrogen-SIRT1 axis shifts, and NAD+ precursors are being studied partly for their potential to offset some of that metabolic drift. This is an area of active research, not established therapy.

What Is Reishi Mushroom and Why Do Women Take It?

Reishi (Ganoderma lucidum) is an adaptogenic fungus with a long history in East Asian medicine. Its primary active compounds are beta-glucan polysaccharides and lanostane-type triterpenes, particularly ganoderic acids.

Women use reishi for several reasons that map onto real physiological concerns: sleep disturbance, immune dysregulation, stress, and fatigue. All of these symptoms peak during perimenopause and postpartum periods.

Immune-modulating mechanism

Reishi beta-glucans bind to Dectin-1 and complement receptor 3 on macrophages and NK cells, triggering cytokine cascades that can both stimulate and suppress immune responses depending on dose and immune baseline. A 2012 randomized trial in healthy adults found that reishi extract increased NK cell activity and CD56+ cell counts. For women with autoimmune conditions such as lupus, Hashimoto's thyroiditis, or rheumatoid arthritis, this immune stimulation is a meaningful caution, not a theoretical one.

Anticoagulant properties

Reishi triterpenes inhibit platelet aggregation by blocking ADP- and collagen-induced clumping. In vitro and animal data show inhibition of thromboxane B2 synthesis. Human anticoagulant trial data are sparse, but the signal is consistent enough that the Natural Medicines database rates the combination of reishi with anticoagulant or antiplatelet drugs as a moderate interaction requiring monitoring.

Does Reishi Interact With NMN or NR Directly?

The short answer is: no known direct pharmacokinetic interaction exists between reishi and NMN or NR.

NMN and NR are water-soluble B3 derivatives metabolized through the salvage and de novo NAD+ synthesis pathways. Reishi compounds are primarily metabolized hepatically via cytochrome P450 enzymes, but current evidence does not place NMN or NR as significant CYP substrates, inducers, or inhibitors. There is no documented competition for the same transporters or metabolic enzymes.

This means the interaction concern is pharmacodynamic, not pharmacokinetic. The two supplements do not meaningfully alter each other's absorption, distribution, or elimination. What they may do is act on overlapping biological systems in ways that could add up in certain clinical contexts.

The immune-modulation overlap

NMN raises NAD+, which feeds SIRT1 and PARP1 activity. Both enzymes influence inflammatory signaling. A 2023 study in Aging Cell found that NMN supplementation at 300 mg/day in older adults modestly reduced circulating IL-6 and TNF-alpha over 12 weeks. Reishi can push cytokines in either direction. Whether combining them produces additive anti-inflammatory effects or unpredictable immune modulation in women with existing immune conditions is genuinely unknown. No published human trial has studied this combination.

The WomanRx clinical framework for evaluating this combination uses three questions: Does your immune system need modulating right now? Are you on any anticoagulant, antiplatelet, or immunosuppressant therapy? And are you in a life stage where either supplement carries explicit contraindications? If any answer is yes, you need individualized clinical guidance before combining these supplements.

The anticoagulant dimension

NMN and NR do not carry known anticoagulant activity. If you are not on any blood-thinning medication and have no bleeding disorder, reishi's platelet-inhibiting effect is the sole anticoagulant consideration in this stack. Combining reishi with NMN or NR does not add anticoagulant risk beyond what reishi contributes alone. However, if you take aspirin, clopidogrel, warfarin, rivaroxaban, or apixaban, adding reishi to your stack, whether or not it includes NMN, warrants a conversation with your prescriber.

Sex-Specific Pharmacology: What Changes for Women?

Hormonal status and NAD+ metabolism

Estrogen influences CD38, an NAD+-consuming enzyme that degrades NAD+ rapidly. Research published in Cell Metabolism showed that CD38 expression rises with age and is a primary driver of age-related NAD+ decline. In post-menopausal women, lower estrogen may correlate with higher CD38 activity, meaning NAD+ turnover is faster and precursor supplementation may theoretically need higher doses to achieve the same intracellular effect. This is a hypothesis based on mechanistic data, not a proven clinical dosing recommendation.

Menstrual cycle considerations

No published data exist on how menstrual cycle phase affects NMN or NR pharmacokinetics in premenopausal women. Reishi's platelet inhibition is worth flagging for women with already heavy menstrual bleeding (menorrhagia), which affects roughly one in three women of reproductive age. Adding a platelet-inhibiting supplement to a heavy-flow cycle is a specific practical concern that most generic supplement guides ignore.

PCOS and metabolic considerations

Women with PCOS often have elevated oxidative stress, mitochondrial dysfunction, and insulin resistance, precisely the targets that NAD+ precursors are being studied for. A 2022 study in Frontiers in Endocrinology found that NAD+ pathway dysregulation is measurable in granulosa cells from women with PCOS. Reishi has been studied in metabolic contexts as well, with modest blood-glucose-lowering signals in some trials. The combination has not been tested in PCOS populations. Women with PCOS who are also trying to conceive should read the pregnancy section below carefully.

Thyroid and autoimmune disease

Hashimoto's thyroiditis affects roughly 5% of women and is the most common cause of hypothyroidism. Reishi's immune-stimulating beta-glucan activity could theoretically aggravate autoimmune thyroid inflammation. NMN and NR are not directly implicated in thyroid autoimmunity, but SIRT1 activation modulates T-regulatory cell function, which intersects with autoimmune pathways. Women with active Hashimoto's or any autoimmune condition should consult their clinician before starting either supplement, regardless of the combination.

Perimenopause and Post-Menopause: Where This Combination Gets Most Attention

Perimenopause is the life stage where interest in NMN plus reishi stacks is highest, and where the benefit-to-risk calculus is most nuanced.

Why this stage, specifically

NAD+ precursors are being investigated for perimenopausal fatigue, brain fog, and metabolic shifts. Reishi is widely marketed for perimenopause-related sleep disruption, anxiety, and immune changes. The overlap in target symptoms drives women to combine them.

The Menopause Society's 2023 position statement on nonhormone therapies does not endorse NMN, NR, or reishi for menopause symptom management due to insufficient evidence. That is the honest clinical baseline you should start from, not marketing claims.

What limited perimenopausal data exist

A randomized, double-blind trial by Igarashi et al. (2022) enrolled 80 Japanese women aged 40 to 60 and found that 250 mg/day of NMN for 12 weeks significantly increased blood NAD+ levels and improved self-reported fatigue scores compared to placebo. No reishi arm was included. No adverse events specific to women's hormonal health were reported.

For reishi in perimenopause, evidence is largely anecdotal or from small open-label studies. A 2012 pilot showed immune effects but was not powered for symptom outcomes.

Post-menopause and bone health

NAD+ has downstream effects on SIRT1, which regulates osteoblast differentiation. Osteoporosis affects approximately one in two women over age 50. Whether NAD+ precursors have clinically meaningful effects on bone density in post-menopausal women is not established. No reishi-NMN bone trial exists.

Pregnancy, Lactation, and Contraception

Both NMN and reishi mushroom should be avoided during pregnancy. This is not a precautionary hedge. It reflects a genuine absence of human safety data.

NMN and NR in pregnancy

NMN and NR are not classified under the FDA's legacy A/B/C/D/X pregnancy category system because they are sold as supplements, not drugs. However, nicotinamide (niacinamide), a metabolite downstream of NR, is generally considered safe in food amounts. High-dose NAD+ precursor supplementation is a different matter. Animal studies showed that NMN rescued NAD+ deficiency-related congenital malformations in mice when given early in gestation, but these findings involve pharmacological dosing in a deficiency model, not supplementation in a healthy pregnancy. Human fetal safety data do not exist. No NMN or NR product should be taken during pregnancy without direct obstetric guidance.

For breastfeeding, nicotinamide does transfer into breast milk in food amounts. Whether supplemental NMN or NR meaningfully alters breast milk NAD+ metabolite content is unknown. Caution is warranted. Discuss with your OB or midwife before continuing either supplement postpartum.

Reishi in pregnancy and lactation

Reishi is contraindicated in pregnancy based on animal data showing potential uterotonic effects and immune modulation that may not be appropriate during the immune-tolerant state of pregnancy. Memorial Sloan Kettering's integrative medicine monograph and multiple ethnobotanical safety reviews flag reishi as avoid during pregnancy. Human safety data do not exist. Do not take reishi if you are pregnant, trying to conceive (unless cleared by your reproductive endocrinologist), or breastfeeding.

Contraception note

Neither NMN, NR, nor reishi are known to reduce the efficacy of hormonal contraception. No CYP3A4 induction has been established for NMN or NR at supplemental doses. Reishi has shown modest CYP inhibitory effects in some in vitro models, but clinical significance in women on oral contraceptives has not been demonstrated. If you are on a combined oral contraceptive and add reishi, monitor for any unexpected spotting or side effect changes and report them to your prescriber.

Who This Is Right For, and Who Should Pause

Women who may reasonably combine NMN or NR with reishi

• Healthy, non-pregnant women aged 35 and older interested in longevity support
• Perimenopausal women with fatigue and sleep complaints who are not on anticoagulant therapy
• Post-menopausal women without autoimmune disease or active bleeding risk
• Women who have discussed both supplements with their clinician and have no contraindications

Women who should not combine them without clinical guidance

• Anyone currently pregnant, trying to conceive, or breastfeeding
• Women on warfarin, apixaban, rivaroxaban, clopidogrel, or daily aspirin
• Women with active autoimmune conditions (lupus, Hashimoto's, rheumatoid arthritis, inflammatory bowel disease)
• Women with heavy menstrual bleeding or a known platelet disorder
• Women on immunosuppressant medications after organ transplant or for autoimmune disease
• Women with liver disease (reishi is hepatically cleared; rare cases of reishi-associated hepatotoxicity have been reported in case literature)

Practical Dosing and Monitoring Guidance

No dose-separation window between NMN/NR and reishi is supported by pharmacokinetic evidence. Since the concern is pharmacodynamic rather than kinetic, taking them at different times of day does not reduce the biological interaction potential.

Common commercially studied doses:

• NMN: 250 to 500 mg/day orally, based on trials including Igarashi et al. and Yoshino et al.
• NR: 250 to 1,000 mg/day, based on Trammell et al. (2016) pharmacokinetic data
• Reishi extract: 1.5 to 9 g/day dried mushroom equivalent, or 1 to 1.5 mg/day triterpene-standardized extract

If you are healthy and choose to take both, a practical monitoring approach includes:

1. Baseline CBC and liver function panel before starting
2. Recheck at 12 weeks if using doses above the lower range
3. Stop reishi immediately if you develop unusual bruising, prolonged bleeding from cuts, or jaundice
4. Report any new autoimmune symptoms to your physician without delay

The Evidence Gap: What We Still Do Not Know

Women have been historically underrepresented in NAD+ precursor trials. The Yoshino et al. Trial that enrolled post-menopausal women with prediabetes is a notable exception; it found that 250 mg/day NMN for 10 weeks improved muscle insulin sensitivity. Most other published NMN and NR trials enrolled mixed-sex or predominantly male cohorts. Sex-disaggregated pharmacokinetic data for NMN or NR in women across reproductive stages are absent from the published literature.

No published human trial has studied NMN or NR combined with reishi mushroom. All interaction guidance here is extrapolated from individual compound data, mechanistic reasoning, and pharmacological principles. That extrapolation is clearly labeled as such throughout this article, and it is the honest limit of current evidence.

As stated in the 2023 NMN clinical review in Nutrients: "Future clinical trials should prioritize sex-stratified analyses and include women across reproductive stages to enable evidence-based prescribing." That recommendation remains unmet as of this writing.